Company research
DYNAVAX TECHNOLOGIES CORP
CIK 1029142Updated Sep 24, 2026
Securities
Historical securities (2)
DVAX · NASDAQ · equity · closed Feb 7, 2022DVAXW · NASDAQ · warrant · closed Feb 7, 2022DVAX price & chart
Historical security
This listing closed Feb 7, 2022. Live provider charts are shown only for current listings.
About the company
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. Dynavax has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and the United Kingdom for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant. For more information about Dynavax’s marketed products and development pipeline, visit www.dynavax.com.
In the news
No coverage from other publishers is available.
Financials
FY 2024 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 986,256,000Source | 997,096,000Source | 985,850,000Source | 1,039,246,000Source |
| Property, Plant and Equipment, NetUSD | 39,001,000Source | 37,297,000Source | 37,596,000Source | 35,020,000Source |
| GoodwillUSD | 1,946,000Source | 2,067,000Source | 2,006,000Source | 2,125,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 95,883,000Source | 150,279,000Source | 202,004,000Source | 436,189,000Source |
| Inventory, NetUSD | 70,054,000Source | 53,290,000Source | 59,446,000Source | 61,335,000Source |
| Assets, CurrentUSD | 848,941,000Source | 859,120,000Source | 916,985,000Source | 972,520,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 18,147,000Source | 18,995,000Source | 85,629,000Source | 73,764,000Source |
| Operating Lease, Right-of-Use AssetUSD | 21,608,000Source | 24,287,000Source | 25,745,000Source | 25,964,000Source |
| Other Assets, NoncurrentUSD | 74,760,000Source | 74,325,000Source | 3,311,000Source | 3,398,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 389,457,000Source | 375,024,000Source | 404,837,000Source | 816,872,000Source |
| Stockholders’ equity: | ||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | — |
| Common Stock, Value, IssuedUSD | 125,000Source | 130,000Source | 128,000Source | 123,000Source |
| Retained Earnings (Accumulated Deficit)USD | -903,275,000Source | -930,584,000Source | -924,195,000Source | -1,217,351,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -4,722,000Source | -2,108,000Source | -5,438,000Source | -2,266,000Source |
| Stockholders' Equity Attributable to ParentUSD | 596,799,000Source | 622,072,000Source | 581,013,000Source | 222,374,000Source |
| Additional Paid in Capital, Common StockUSD | 1,504,671,000Source | 1,554,634,000Source | 1,510,518,000Source | 1,441,868,000Source |
| Liabilities and EquityUSD | 986,256,000Source | 997,096,000Source | 985,850,000Source | 1,039,246,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 78,634,000Source | 62,195,000Source | 150,074,000Source | 556,402,000Source |
| Operating Lease, Liability, CurrentUSD | 4,175,000Source | 4,496,000Source | 3,631,000Source | 2,577,000Source |
| Accounts Payable, CurrentUSD | 9,061,000Source | 5,245,000Source | 3,211,000Source | 2,600,000Source |
| Operating Lease, Liability, NoncurrentUSD | 26,388,000Source | 29,720,000Source | 32,801,000Source | 34,316,000Source |
| Other Liabilities, NoncurrentUSD | 244,000Source | 74,000Source | 384,000Source | 5,664,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 61,066,000Source | 49,448,000Source | 30,719,000Source | 49,796,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 546,000,000Source |
| Deferred Revenue, CurrentUSD | — | — | — | 55,400,000Source |
| Deferred Tax Liabilities, NetUSD | 6,815,000Source | 9,041,000Source | 9,796,000Source | 9,437,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | — | 0Source |
cash flow · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation and amortization | — | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 52,619,000Source | 42,592,000Source | 32,915,000Source | 21,285,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in InventoriesUSD | 19,909,000Source | -3,909,000Source | 32,399,000Source | 234,000Source |
| Increase (Decrease) in Accounts PayableUSD | 3,899,000Source | 1,952,000Source | 691,000Source | -767,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 66,512,000Source | 100,563,000Source | 62,716,000Source | 335,528,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -18,035,000Source | -153,928,000Source | -315,995,000Source | 14,225,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 6,352,000Source | 4,104,000Source | 7,139,000Source | 9,477,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | 100,000,000Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -102,017,000Source | 1,386,000Source | 19,525,000Source | 55,776,000Source |
| Repayments of Long-term DebtUSD | — | 0Source | 0Source | 190,194,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -54,402,000Source | -51,655,000Source | -234,197,000Source | 404,098,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 96,154,000Source | 150,556,000Source | 202,211,000Source | 436,408,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 5,638,000Source | 5,638,000Source | 5,638,000Source | 9,815,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -862,000Source | 324,000Source | -443,000Source | -1,431,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | 0Source | 2,774,000Source | 3,075,000Source |
| Amortization of Debt Issuance CostsUSD | 1,158,000Source | 1,121,000Source | 1,094,000Source | 669,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | 546,000,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | 300,000Source | -100,000Source | 100,000Source | 900,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | -2,400,000Source | 1,100,000Source | -1,800,000Source | 2,500,000Source |
| Gain (Loss) on Termination of LeaseUSD | -3,500,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | 0Source | 0Source | -5,232,000Source |
| Gain (Loss) on Disposition of Assets for Financial Service OperationsUSD | 0Source | 1,000,000Source | 1,000,000Source | 1,000,000Source |
| GoodwillUSD | 1,946,000Source | 2,067,000Source | 2,006,000Source | 2,125,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | — |
| Income Tax Expense (Benefit)USD | 3,546,000Source | 2,022,000Source | 1,143,000Source | 808,000Source |
| InterestExpenseNonoperatingUSD | 6,794,000Source | — | — | — |
| Inventory Write-downUSD | 3,144,000Source | 0Source | 34,288,000Source | 2,588,000Source |
| Investment Income, InterestUSD | 36,464,000Source | 31,993,000Source | 7,912,000Source | 140,000Source |
| Net Income (Loss) Attributable to ParentUSD | 27,309,000Source | -6,389,000Source | 293,156,000Source | 76,713,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 27,309,000Source | -6,389,000Source | 292,873,000Source | 72,144,000Source |
| Operating Lease, ExpenseUSD | 5,702,000Source | 5,563,000Source | 6,222,000Source | 6,265,000Source |
| Other Nonoperating Income (Expense)USD | 293,000Source | -152,000Source | 111,000Source | 922,000Source |
| Proceeds from Issuance of Common StockUSD | — | 0Source | 0Source | 28,156,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 52,619,000Source | 42,592,000Source | 32,915,000Source | 21,285,000Source |
income statement · annual statements
| Line item | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Total RevenueUSD | 277,246,000Source | 232,284,000Source | 722,683,000Source | 439,442,000Source |
| Selling, General and Administrative ExpenseUSD | 170,373,000Source | 152,946,000Source | 131,408,000Source | 100,156,000Source |
| Operating Income (Loss)USD | -4,122,000Source | -37,028,000Source | 283,522,000Source | 134,486,000Source |
| Other Nonoperating Income (Expense)USD | 293,000Source | -152,000Source | 111,000Source | 922,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | 30,855,000Source | -4,367,000Source | 294,299,000Source | 77,521,000Source |
| Income Tax Expense (Benefit)USD | 3,546,000Source | 2,022,000Source | 1,143,000Source | 808,000Source |
| Net Income (Loss) Attributable to ParentUSD | 27,309,000Source | -6,389,000Source | 293,156,000Source | 76,713,000Source |
| Earnings Per Share, BasicUSD per share | 0.21Source | -0.05Source | 2.32Source | 0.62Source |
| Earnings Per Share, DilutedUSD per share | 0.2Source | -0.05Source | 1.97Source | 0.57Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 130,047,000Source | 128,733,000Source | 126,398,000Source | 116,264,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 133,344,000Source | 128,733,000Source | 150,797,000Source | 133,006,000Source |
| Interest Expense (non-operating)USD | 6,794,000Source | — | — | — |
| Additional Financial Items | ||||
| Cost of Goods and Service, Excluding Depreciation, Depletion, and AmortizationUSD | 49,445,000Source | 50,167,000Source | 262,153,000Source | 173,572,000Source |
| Costs and ExpensesUSD | 281,368,000Source | 269,312,000Source | 439,161,000Source | 304,956,000Source |
| Current Income Tax Expense (Benefit)USD | 3,546,000Source | 2,022,000Source | 1,143,000Source | 808,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 4,627,000Source | 4,342,000Source | 3,812,000Source | 4,296,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | 300,000Source | -100,000Source | 100,000Source | 900,000Source |
| Goodwill, Impairment LossUSD | 0Source | 0Source | 0Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | 28,083,000Source | -6,275,000Source | 292,460,000Source | — |
| Interest ExpenseUSD | — | 6,757,000Source | 6,732,000Source | 11,176,000Source |
| Interest Expense, DebtUSD | 6,794,000Source | 6,757,000Source | 6,732,000Source | 4,224,000Source |
| Interest Income (Expense), NetUSD | 0Source | — | — | — |
| Investment Income, InterestUSD | 36,464,000Source | 31,993,000Source | 7,912,000Source | 140,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | 27,309,000Source | -6,389,000Source | 292,873,000Source | 72,144,000Source |
| Operating Lease, ExpenseUSD | 5,702,000Source | 5,563,000Source | 6,222,000Source | 6,265,000Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | — | 0Source |
| Research and Development ExpenseUSD | 61,550,000Source | 54,886,000Source | 46,600,000Source | 32,228,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | 52,619,000Source | 42,592,000Source | 32,915,000Source | 21,285,000Source |
| Undistributed Earnings (Loss) Allocated to Participating Securities, BasicUSD | — | — | -283,000Source | -4,569,000Source |
Filing attachments
d945003dex41.htm · 8-K · 2026-02-10
EX-4.1 4 d945003dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 FIRST SUPPLEMENTAL INDENTURE FIRST SUPPLEMENTAL INDENTURE, dated as of February 10, 2026 (this “Supplemental Indenture”), by and between Dynavax Technologies Corporation, a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), as trustee (the “Trustee”), supplements the Indenture dated May 13, 2021 (as supplemented or otherwise modi…
Read attachment ↗d945003dex42.htm · 8-K · 2026-02-10
EX-4.2 5 d945003dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 FIRST SUPPLEMENTAL INDENTURE FIRST SUPPLEMENTAL INDENTURE, dated as of February 10, 2026 (this “Supplemental Indenture”), by and between Dynavax Technologies Corporation, a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), supplements the Indenture dated March 13, 2025 (as supplemented or otherwise modified prior to the date hereof, the “Indenture”), between th…
Read attachment ↗d82616dex991.htm · 8-K · 2025-12-29
EX-99.1 3 d82616dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline Dynavax stockholders to receive $15.50 in cash, a 39% premium to Dynavax closing share price on December 23, 2025 Emeryville, CA. December 24, 2025. Sanofi announced today that it has entered into an agreement to acquire Dynavax Technologies Corporation (Nasdaq: DVAX), a publicly traded vaccines company with a ma…
Read attachment ↗d57006dex991.htm · 8-K · 2025-08-21
EX-99.1 2 d57006dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerability profile, including lower solicited local and systemic post-injection reactions, versus Shingrix Z-1018 demonstrated robust immune responses in all dose arms, including a 100% humoral v…
Read attachment ↗d57006dex992.htm · 8-K · 2025-08-21
EX-99.2 3 d57006dex992.htm EX-99.2 EX-99.2 Corporate Presentation Using Proven, Innovative Adjuvant Technology to Help Protect the World Against Infectious Diseases August 2025 Nasdaq: DVAX Exhibit 99.2 Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Dynavax's financial results and market share as of and for the qu…
Read attachment ↗d935304dex41.htm · 8-K · 2025-03-13
EX-4.1 2 d935304dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 DYNAVAX TECHNOLOGIES CORPORATION AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of March 13, 2025 2.00% Convertible Senior Notes due 2030 TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS Section 1.01. …
Read attachment ↗